Opus Genetics, Inc. (IRD) Stock Grade

About Opus Genetics, Inc.'s fundamentals

Opus Genetics is a biotechnology company with a market capitalization of $417.0 million that is currently unprofitable, posting a net margin of -349.3% and reporting a net loss in its latest annual statement. The company is demonstrating strong revenue growth of 29.2% year-over-year, suggesting expanding business activity despite its loss position. With no dividend yield and negative profitability metrics, the company is in a typical early-stage biotech profile where growth investments are outpacing current revenues. Traditional valuation metrics like P/E ratio and return on equity are not applicable given the company's loss-making status.